If you had asked me if I knew what Alk + Lung Cancer was in early 2023, my answer would have been a No. I had heard of Lung Cancer and assumed that it was a smoker’s disease but I never thought much about going any deeper. So when I got diagnosed, clearly I had a lot to learn.
The process was overwhelming to say the least – sifting through various websites online.
So I thought it was a fitting topic to write about on my blog.
Lung cancer is often thought of as one uniform disease, but in reality, there are many subtypes—each with its own causes, behaviours, and treatments. One particular type that has become increasingly important is ALK-positive lung cancer (often abbreviated ALK+ NSCLC). If you or a loved one has been diagnosed with this, understanding what “ALK positive” means, what treatment options are available, and what to expect can make a big difference in navigating the journey ahead.
What Does “ALK-Positive” Mean?
ALK stands for anaplastic lymphoma kinase, a gene that in healthy people plays roles in development, especially in the nervous system. In ALK-positive lung cancer, something goes wrong: the ALK gene fuses or rearranges with another gene (most commonly EML4), creating a mutation/addition called an ALK gene fusion. This faulty gene sends signals that tell cells to grow and divide uncontrollably.
Because of that, tumors that are ALK+, behave differently. They grow, spread, and respond to treatments differently compared to lung cancers without that mutation. Knowing whether lung cancer is ALK+ is therefore crucial, because it opens up options for targeted therapies which can be much more effective and less harsh than traditional chemotherapy.
Who Gets ALK-Positive Lung Cancer?
If you’ve got a pair of lungs, you can get Lung Cancer with this mutation.
Here are some patterns found in clinical data:
- ALK+ NSCLC is relatively rare: about 3-5% of non-small cell lung cancer (NSCLC) cases in Western populations.
- It tends to appear in younger adults, often under age 50.
- Many people who develop ALK+ lung cancer are non-smokers or light smokers.
- The cancer often presents as adenocarcinoma (a histological subtype) rather than other NSCLC types.
These factors are not absolute, but they help explain why ALK+ lung cancer is considered somewhat distinct from many of the “classic” lung cancer cases tied strongly to long smoking histories.
Diagnosing ALK+ Lung Cancer
Because treatments depend heavily on whether ALK fusions are present, diagnosing ALK+ involves:
- Biomarker testing: Tissue biopsies or in some cases liquid biopsies (blood tests) to look for gene rearrangements. Tests like IHC (immunohistochemistry), FISH (fluorescence in situ hybridization), or next-generation sequencing are commonly used.
- Imaging: CT scans, PET scans, MRI (especially of the brain) to see where cancer may have spread. ALK+ cancers often metastasize to the brain, so imaging for brain involvement is especially important.
Early detection and accurate genetic profiling are essential for choosing the best treatment path.
Treatment Options: Targeted Therapy & Beyond
One of the biggest advances in ALK+ lung cancer care has been targeted therapy—drugs designed specifically to block the faulty ALK fusion protein. These are called ALK inhibitors (or ALK TKIs: Tyrosine Kinase Inhibitors).
Some of the ALK inhibitors currently used include:
- Crizotinib – one of the earlier medicines approved for ALK+ lung cancer.
- Ceritinib – especially useful if resistance builds to earlier drugs, or for certain cases.
- Alectinib, Brigatinib, Lorlatinib – newer generation ALK inhibitors with better penetration into the brain and often fewer side effects.
- Ensartinib – recently approved for ALK+ lung cancer that is locally advanced or metastatic.
These targeted treatments tend to work better than traditional chemotherapy in ALK+ NSCLC, especially in cases where the cancer has spread beyond the lungs. Also, because ALK+ lung cancer can spread to the brain, using inhibitors that cross into the central nervous system (CNS) is often crucial.
In addition to ALK inhibitors, chemotherapy, radiation therapy, and occasionally surgery may still have roles, depending on stage of disease, overall health, and how the tumor responds to initial treatment.
Prognosis & What To Expect
While no two journeys are the same, the outlook for ALK+ lung cancer has improved dramatically in recent years.
- Thanks to the development of potent ALK inhibitors, many people with ALK+ NSCLC are living longer, with better quality of life than was possible with older treatments.
- Studies show that in the metastatic setting, ALK inhibitors are associated with significantly improved overall survival compared to older therapies.
- The probability of disease spreading to the brain is high, so monitoring, and using drugs that can address brain metastases, is essential.
That said, resistance to ALK inhibitors can develop over time. This means that sometimes a drug stops working as well, or the cancer starts to grow in different ways. Thankfully, there are newer ALK inhibitors and combination strategies under research to address resistance.
If you’re new to Cancer and have recently been diagnosed and you are looking for initial basic information, I hope you find this useful. I am living with Stage 4 Alk+ Lung Cancer and I can tell you from lived experience, there is always Hope !
Leave a Reply